Friday’s encouraging stage 1b/2a results for amycretin persuaded numerous experts that Novo Nordisk will certainly concentrate on the brand-new weight-loss prospect over cagrisema.
发布者:BY IDA JORGENSEN,转转请注明出处:https://robotalks.cn/analysts-new-data-pushes-novos-cagrisema-into-the-background/